potentiated the mitogenic effect of IGF-I and achieved statistical significance at 30 and 100 pmol/l (p <0.05). This potentiation was also studied in vivo. The right hindlimbs of rats weighing 150 g were infused intra-arterially by an osmotic minipump with graded doses ofIGF-I (0.1 to 0.4 nmol/day) and/or PTH (0.27 nmol/day) for 7 days. The rate of trabecular bone apposition (formation) was measured by double tetracycline labelling and compared with the contralateral uninfused limb which acted as the control. Histomorphometric data revaled that neither IGF-I nor PTH alone had a significant effect on trabecular bone apposition rate compared with control limbs. The co-infusion of IGF-I (0.4 nmol/day) and PTH (0.27 nmol/ day) resulted in a marked increase in trabecular bone apposition rate. The results of 2 studies were significant at p < 0.01. These data suggest that PTH potentiates the effect of IGF-I on bone formation both in vivo and in vitro.
Insulin-like growth factors are anabolic polypeptides that are the major regulators of skeletal growth (1) . There are two principal IGFs, IGF-I and IGF-II. They are growth hormone-dependent, have insulin-like activity, and are transported in plasma in an inactive form bound primarily to a large mole¬ cular weight carrier protein (2) .
There is considerable evidence that IGF-I affects longitudinal bone growth. Clinically, IGF-I defi¬ ciency or cellular resistance to its actions results in decreased bone growth and sustained IGF-I excess in childhood results in acro-gigantism (1, 3 (11, 16, 17) . The (Fig. 3) . Co there was a significant increase in the trabecular bone apposition rate caused by the co-administra¬ tion of the two hormones. The combined data from these two experiments is presented in Fig. 3 . The increase was significant at p < 0.01. The serum calcium and phosphorus levels were depressed after IGF-I and IGF-I plus PTH adminis¬ trations (data not shown). Since sham-operated animals also have depressed levels, these changes are probably related to the effects of anesthesia and surgery.
Discussion
Physiologic, non-mitogenic concentrations of PTH significantly potentiated the mitogenic effect of IGF-I on cultured chick embryonic osteoblast-like cells. In vivo this potentiation between PTH and IGF-I was also demonstrated because co-arterial infusion of inactive doses of PTH and IGF-I into the rat hindlimbs caused a marked increase in the bone apposition rate. The synergism between IGF-I and PTH may explain the bone-stimulating effects of PTH in both intact and thyroparathyroidectomized rats (19) (20) . PTH could potentiate the circulating IGF-I and enhance the anabolic effect of IGF-I on bone tissues.
The inability of physiologic PTH concentrations to affect the proliferation of osteoblasts in vitro re¬ plicates our earlier finding (11) . The discrepancy with previous studies that described stimulation may be due to their using: 1 (36) (37) (38) . However, when tested clincially, fluoride treatment did not reduce the hip fracture incidence of the patients (36) . Furthermore, these treatments may have in¬ tolerable side effects, which frequently result in cessation of therapy. The positive anabolic interac¬ tion between IGF-I and PTH found in this study could be the basis of future therapy for osteopo¬ rosis.
